Tag: Reneo Pharmaceuticals
Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies
Reneo Pharmaceuticals has been granted the orphan drug designation (ODD) for its lead drug candidate REN001 from the US Food and Drug Administration (FDA) for ... Read More
Reneo Pharmaceuticals launches REN001 clinical trial in McArdle disease
Reneo Pharmaceuticals has initiated a phase 1b clinical trial of REN001 in glycogen storage disease type V (GSD V), also called McArdle disease. The California-based ... Read More